Apollo Hospitals Enterprise Ltd
Apollo Hospitals Enterprise Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #6 of 33 in Healthcare Services
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
2 of 3 strong
The short version
Full-year revenue growth target for hospitals is around 18% to 20%. Healthcare Services: - Revenue growth guidance of 20% for FY27.
From Apollo Hospitals Enterprise Ltd's Q1 FY27 earnings-call transcript · updated 5 Sept 2026.
Revenue & Sales Performance
- Full-year revenue growth target for hospitals is around 18% to 20%.
- Established hospitals expected to grow 13% to 14% over the next 24 months.
- New hospitals are expected to add around 7% to revenue growth during the same period.
- IP volume growth for established units guided at roughly 7% to 8%.
- Bangladesh patient volumes normalizing, resulting in higher volume growth (60%-70% recovery).
- Digital pharmacy and diagnostics businesses aiming for 20%-30% growth.
- Insurance business is growing rapidly (around 80% growth) but still in investment phase, expected to breakeven by Q3 of FY27.
2 more points from Apollo Hospitals Enterprise Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Apollo Hospitals Enterprise Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Apollo Hospitals is commissioning new hospitals, including the upcoming Gurgaon hospital with a soft launch in September and full opening in October, contributing to revenue from Q4 onwards.
- Plans for a new Proton center in Delhi are underway, with location options to be shared soon; the existing Chennai Proton center is operating near full capacity.
- Capital investment continues to focus on expanding and upgrading facilities, such as renovation of the Teynampet hospital in Chennai.
- The company is also investing in digital businesses, diagnostics, primary care, and insurance platforms to build an integrated healthcare ecosystem.
- The mother and child business transaction is pending regulatory clearance, after which the focus will intensify on diagnostics and primary care growth.
2 more points from Apollo Hospitals Enterprise Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Apollo Hospitals Enterprise Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Apollo Hospitals Enterprise Ltd — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹6.6K Cr, net profit ₹551 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Apollo Hospitals Enterprise Ltd's management said in earlier quarters
- Q4 FY25 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q3 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Healthcare Services this season
- Aatmaj Healthcare Ltd (Q1 FY27)
Revenue for Q1 FY 2026-27: ₹8.13 crore . Key investor presentation takeaways from Aatmaj Healthcare Ltd's Q1 FY27 investor presentation — and how it ranks again
- Asarfi Hospital Ltd (Q1 FY27)
Q1'FY27 consolidated revenue from operations: ₹47.5 Cr, up 32.8% YoY (vs ₹35.7 Cr in Q1'FY26) . Key investor presentation takeaways from Asarfi Hospital Ltd's Q
- KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
- 3B Blackbio DX Ltd (Q1 FY27)
Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. Key concall…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM Quality Care LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Apollo Hospitals Enterprise Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Apollo Hospitals Enterprise Ltd Q1 FY27 results?
Full-year revenue growth target for hospitals is around 18% to 20%. Healthcare Services: - Revenue growth guidance of 20% for FY27.
What is Apollo Hospitals Enterprise Ltd share price analysis?
Apollo Hospitals Enterprise Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 59.4 with a market cap of ₹124,992 Cr. Investors should review the full earnings analysis for detailed insights.
Is Apollo Hospitals Enterprise Ltd planning capital expenditure?
Apollo Hospitals is commissioning new hospitals, including the upcoming Gurgaon hospital with a soft launch in September and full opening in October, contributing to revenue from Q4 onwards.
Keep Apollo Hospitals Enterprise Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.